PARP Inhibitor Drugs May Now be Standard Part of Follow-up Therapy for Some Ovarian Cancer Patients

On the strength of the results of a major international clinical trial, there is now a new standard of care for patients with an advanced form of ovarian cancer who have responded to initial chemotherapy. The trial, dubbed SOLO-1, found that these patients – newly diagnosed with ovarian cancer that carries a mutation in the … Read more

Living for Today, Metastatic Breast Cancer Patient Has ‘All I Need’

Krista Lawrence likes to joke with her two adult children that they don’t need to get married and have their own kids just because she has metastatic breast cancer. In fact, thanks to her excellent response to a clinical trial at the Susan F. Smith Center for Women’s Cancers at Dana-Farber, Lawrence is enjoying each … Read more

Trials Open New Avenues of Endometrial Cancer Treatment

In recent years, there has been a dearth of clinical trials studying new approaches to how endometrial cancer, which forms in the lining of the uterus, is treated. That is changing rapidly, however, as basic research into the disease spurs the testing of novel drugs and drug combinations. A host of clinical trials—including four led … Read more

‘Organoids’ Could Aid Cancer Drug Selection

Tests on living “organoids” created from patients’ ovarian cancer cells proved more accurate than DNA sequencing in predicting tumors’ sensitivity or resistance to chemotherapy drugs – and combining the two methods worked even better, say scientists at Dana-Farber Cancer Institute. The investigators report in Cancer Discovery that ovarian cancer organoids – tiny, three-dimensional spheres of cells … Read more